Centre hospitalier de l'Université de Montréal (CHUM)
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Enrolled in PERa (CHUM CER 17.032) and randomly selected for ANCHOR-Prostate.
Diagnosis of hormone-sensitive metastatic prostate cancer having responded to systemic therapy.
PSA non-progressing
ECOG 0-2
Metastatic disease suitable for MDRT.
Primary tumor must have received definitive local treatment (surgery or radiotherapy) with no evidence of local recurrence, or be planned for treatment at the time of MDRT.
You may not be if
Planned intermittent systemic therapy.
Planned radio-ligand therapy.
Clareo Health | Radiotherapy to Consolidate Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
